Pharmaceutical Technology

MAY 19, 2023

The US Food and Drug Administration (FDA) has approved AbbVie’s Rinvoq (upadacitinib) for patients with Crohn’s disease who do not respond to TNF blockers, a common immune suppressant treatment for the condition. Data from two Phase III studies, U-EXCEED and U-EXCEL, involving 857 patients was used to support the approval.

Food and Drug Administration 105

Food and Drug Administration FDA Sales Food 105

World of DTC Marketing

MARCH 28, 2022

Patients who are overweight, consume more than a couple of drinks a week and don’t exercise SHOULD pay more. If the trend continues at the current rate, millennial treatment costs are still projected to be close to $4,500 annually, roughly 33 percent higher than Generation X’s at a comparable age, by 2027.

Insurance 249

Insurance Ethics Healthcare Healthcare 249

European Pharmaceutical Review

FEBRUARY 8, 2023

The number of blood cancer patients receiving CD19-directed CAR-T therapies is set to boom over the next decade from approximately 3,700 patients in 2021 to nearly 13,500 patients in 2031. This allows for a large total eligible patient population despite capturing less patient share relative to other CD19 CAR-T agents.

Marketing 98

Marketing Sales Physicians Patients 98

European Pharmaceutical Review

MAY 4, 2023

Data announced at the European Lung Cancer Congress (ELCC) earlier this month revealed the long-term efficacy and safety of RYBREVANT ® (amivantamab) in patients with post-platinum EGFR Ex20ins-mutated advanced non-small cell lung cancer (NSCLC). 3 , 4 There is a high unmet need for novel and targeted therapies for this patient population.

Food and Drug Administration 98

Food and Drug Administration Safety Patients Medicine 98

European Pharmaceutical Review

NOVEMBER 20, 2023

This will ensure that patients have rapid access to new treatment options and make us more independent from fragile supply chains,” commented Professor Dr Karl Lauterbach, Federal Minister of Health. But we will continue to improve the framework conditions for research and production.

Manufacturing 98

Manufacturing Medicine Biopharma Engineering 98

European Pharmaceutical Review

JULY 18, 2022

Nebido is also patented until March 2024 in the European Union and until May 2027 in the United States. Too few of these patients receive appropriate treatment. We are committed to facilitating access to treatment for even more patients in need,” commented Gabriel Baertschi, CEO of Grünenthal.

Medicine 98

Medicine Physicians Competition Patients 98

pharmaphorum

JANUARY 10, 2023

Astellas has licensed rights to a drug developed by Selecta Biosciences that could make more patients eligible for treatment with its gene therapy for inherited neuromuscular disorder Pompe disease. There has been no update from Astellas since the clinical hold was imposed last June.

Patients 116

Patients FDA 116

Penrod

APRIL 1, 2024

These policies aim to enhance prior authorization and efficiency for care providers, payers and patients. CMS has extended payers’ compliance dates to the new rule to January 2027, giving payers more time for implementation. Payers would be required to expand patient access APIs and implement Provider Access APIs.

Electronics 52

Electronics Insurance Healthcare Healthcare 52

European Pharmaceutical Review

JUNE 15, 2023

Importantly, they identify potential sources of microbial contamination and assess their risk to patients. This microbial contamination can lead to a range of adverse events, such as infections, adverse reactions, or device failures, which can compromise patient safety and health outcomes. Sharma et al.

Manufacturing 103

Manufacturing Medical Safety Transportation 103

European Pharmaceutical Review

DECEMBER 2, 2022

The facility is planned for completion in 2027. We continue to invest in our global manufacturing infrastructure to bring much-needed medicines and vaccines to patients, around the world, and to deliver the next scientific breakthroughs.”. In 2021, the company invested €40 million in its Grange Castle facility. The post Pfizer’s €1.2

Manufacturing 105

Manufacturing Medicine Networking Medical 105

Medico Reach

APRIL 5, 2022

The use of IoT has grown exponentially in the field of Medicine providing better services to patients. This has transformed the way we analyze Medical Data , Patient information, and Medical device information. between 2022-2027. This along with remote supervision will create a 50% reduction in patient readmissions.

Healthcare 52

Healthcare Healthcare Marketing Medical 52

European Pharmaceutical Review

JANUARY 19, 2023

The contribution will enable the programme to reach additional physicians and medical students, further expanding the initiative that aims to extend the reach of clinical trials in underserved patient populations in US communities. The Winn Award Program has so far trained 114 early-stage investigator physicians.

Food and Drug Administration 98

Food and Drug Administration Physicians Medicine Food 98

Impetus Digital

MARCH 15, 2024

In 2022, global spending on cancer medicines was approximately 196 billion USD, and this number is forecasted to reach $375 billion by 2027. In fact, for the past five years, the number of treated patients with cancer has seen an average annual increase of 5% globally (1). The field of oncology is rapidly growing and evolving.

Recruitment 79

Recruitment Healthcare Provider Patients Healthcare 79

LEVO Health

JULY 15, 2024

billion by 2027. To stand out in this competitive landscape, businesses must focus on patient engagement, comprehensive service offerings, strong marketing and branding, and strategic partnerships with top-tier telehealth service providers like WellSync and medical marketing experts like Levo Health.

Marketing 52

Marketing Side effects Education Medical 52

European Pharmaceutical Review

JANUARY 10, 2023

Treatments identified in the report are predicted to be potential blockbuster drugs by 2027 or have potential to serve unmet patient needs for millions of patients worldwide. The drug can be used to treat a niche group of patients with high unmet need.

Food and Drug Administration 98

Food and Drug Administration FDA Food Medicine 98

pharmaphorum

JANUARY 17, 2023

Preliminary results from a cohort of 101 patients in the study have suggested that they can detect longitudinal change in cognition in Alzheimer’s disease. It reckons the market opportunity for Winterlight’s technology could be worth around $30 million in 2027, and expects it to contribute around £2 million ($2.5

Marketing 101

Marketing Healthcare Healthcare Patients 101

PM360

JULY 13, 2023

1 This increased technology spending has led to industry fragmentation, creating siloed data—which can leave providers with an incomplete picture of a patient’s health record—and an often-cumbersome experience for patients, leaving them to shoulder the burden of managing their own care. billion in 2020 and is expected to reach $381.7

Healthcare 98

Healthcare Healthcare Consulting Healthcare Provider 98

European Pharmaceutical Review

SEPTEMBER 28, 2023

EMA prepares for winter antibiotic shortages PFAS restriction in pharmaceutical manufacturing In its current form, the procedure currently underway could lead to a ban on all PFASs by 2027, with very limited derogations, EFPIA acknowledged. The organisation’s response included results from a patient impact analysis.

Pharmaceutical manufacturing 105

Pharmaceutical manufacturing Manufacturing Pharmaceutical Medicine 105

pharmaphorum

NOVEMBER 18, 2022

At its second attempt, Provention Bio has secured FDA approval for teplizumab, as a treatment to delay late-stage type 1 diabetes (T1D) in at-risk individuals – becoming the first disease-modifying therapy for these patients. Teplizumab is thought to work by preventing the activation of T cells that attack those cells.

FDA 52

FDA Patients Manufacturing Sales 52

PM360

SEPTEMBER 21, 2023

As a mission-driven company and digital healthcare leader, GoodRx has helped patients obtain an estimated 80 million prescriptions they otherwise may not have been able to afford. 1 We have been improving patient affordability for over a decade, across generic and brand medications, including specialty treatments—sometimes by more than 50%.

Prescription 52

Prescription Medical Patients Distribution 52

Medico Reach

SEPTEMBER 12, 2022

Upon immediately subjecting the patient to an X-ray, the barium appears white as doctors observe how it outlines the digestive tract. . Option to treat the patient during endoscopy. But since the patient is already sedated while performing the procedure, the doctor can treat the problem during endoscopy. billion by 2027.

Marketing 52

Marketing Doctors Training Medical 52

pharmaphorum

SEPTEMBER 23, 2022

In a statement , Ionis said that AZD8233 met its objectives in the phase 2b SOLANO trial in patients with hypercholesterolaemia, when given as a monthly 60mg dose, reducing LDL-C levels by 62% compared to placebo after 28 weeks, and thereby achieving the study’s primary endpoint. billion in sales by 2027, ahead of Repatha at $2.2

Sales 59

Sales Education Pharma Patients 59

pharmaphorum

JULY 18, 2022

If approved, atogepant is expected to be a strong competitor to Vydura, according to analysts at GlobalData, who point to strong clinical data in episodic and chronic migraine and the availability of three strengths that allows the dose to be more closely matched to a patient’s needs.

Sales 52

Sales Marketing Patients FDA 52

pharmaphorum

SEPTEMBER 22, 2022

The “US-first” mindset will lead to higher proportions of American patients in its clinical trials and investment in “capability and talent” in the US, where it aims to become a top-five player by 2027 – a big advance on its current 10th place. billion by 2024.

Management 52

Management Sales Patients Marketing 52

pharmaphorum

OCTOBER 1, 2022

The latest judgments relate to an attempt by Chinese drugmaker HEC Pharma to bring a generic version of fingolimod to market in the US, and Novartis defense of the 9,187, 405 patent which expires in December 2027.

Competition 52

Competition Pharma Marketing Sales 52

PM360

MAY 21, 2024

From connecting with patients by interactive ads to dabbling into cross-platform integration, here is what our specialists had to say. What are new and effective ways of engaging patients who are now using streaming services? What are new and effective ways of engaging patients who are now using streaming services?

Media 105

Media Healthcare Healthcare Marketing 105

Medico Reach

DECEMBER 2, 2022

billion , and by 2027, it is expected to reach around an exciting amount of 115.1 from 2022 to 2027. Some clinical trials offered by PPD include: Early Development Consulting and Product Development PPD Biotech PPD FSP The site and patient-centered Solutions Clinical Development. billion with a CAGR of 11.0% Medpace Holdings.

Consulting 98

Consulting Specialization Medicine Medical 98

pharmaphorum

JANUARY 9, 2023

Albireo secured approval in the US and Europe for the ileal bile acid transport inhibitor (IBATi) drug in 2021 for the treatment of pruritus (itching) in patients with rare disorder progressive familial intrahepatic cholestasis (PFIC), and has said sales should reach $24 million this year.

Transportation 52

Transportation Sales Leads FDA 52

Clarivate

APRIL 18, 2024

While the key players’ strategies differ, all are focused on bending the cost curve while increasing patient touchpoints and engagement. More recent developments provide a look into Amazon’s interest in treating patients with chronic conditions, including a pharmacy consultation pilot for high-risk seniors with complex medical needs.

Retail 52

Retail Healthcare Healthcare Physicians 52

Pharmaceutical Technology

DECEMBER 16, 2022

GnRH antagonists have an improved safety and efficacy profile compared to the marketed GnRH agonists, which have significant side effects that are unappealing to patients. This therapy is currently in Phase II development and is expected to launch in the US and 5EU in 2027 and 2028, respectively.

Marketing 59

Marketing Side effects Sales Safety 59

pharmaphorum

JULY 18, 2022

. “The acceptance of the filing of proposed biosimilar natalizumab by the European regulatory authorities means we are a critical step closer to getting this important medicine to the patients who need it the most,” said Polpharma Biologics’ chief executive Michael Soldan in a statement.

Competition 52

Competition Marketing Sales Medicine 52

PM360

OCTOBER 24, 2022

Amgen is committed to unlocking the potential of biology for patients suffering from serious illnesses by discovering, developing, manufacturing, and delivering innovative human therapeutics. Amgen is one of the 30 companies that comprise the Dow Jones Industrial Average and is also part of the Nasdaq-100 index. Social Responsibility.

Pharma 40

Pharma Medicine Education Manufacturing 40

PM360

DECEMBER 14, 2022

In its latest venture into the healthcare arena, Amazon is reaching out directly to the consumer via its soon-to-be-launched Amazon Clinic , a virtual health service for patients to see licensed clinicians about common medical issues. billion euros into its new facility where it is planning to hire 400 and 500 new personal by 2027.

Manufacturing 52

Manufacturing Medical Healthcare Healthcare 52

Clarivate

AUGUST 27, 2024

With the global atrial fibrillation market at $6 billion today, that rate of growth would push it to $12 billion by mid-2027, if not sooner, with PFA accounting for about 70% of the market. In addition, the improved safety profile of PFA is making the cost-benefit of ablation an easier calculation for many patients.

Marketing 52

Marketing Competition FDA Electronics 52

Legacy MEDSearch

SEPTEMBER 20, 2022

The SavvyWire is the first and only Sensor-Guided TAVR solution, designed to support TAVR efficiency and lifetime patient management. The TAVR procedure was initially only indicated for inoperable patients with severe symptomatic aortic stenosis, and later for patients at high surgical risk. About OpSens Inc.

FDA 52

FDA Food and Drug Administration Recruitment Physicians 52

PM360

SEPTEMBER 21, 2023

This article covers some of the reasons these drugs were chosen, how the process for price negotiation will occur, and the impact for the industry and for patients. Over the next few weeks, manufacturers will submit a range of clinical, marketing, sales, pricing, and patient data, and then meet with CMS to discuss submissions later this fall.

Manufacturing 111

Manufacturing Marketing Competition Physicians 111

Clarivate

SEPTEMBER 5, 2024

1: CMS obtained steep price cuts in its first round of negotiations Source: The Centers for Medicare & Medicaid Services By 2027, 20 additional drugs per year will be negotiated, including often complex and expensive physician-administered Medicare Part B drugs, such as infusible biologics.

Insurance 52

Insurance Marketing Manufacturing Prescription 52